Patents by Inventor Dilip Manikrao Mondhe

Dilip Manikrao Mondhe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID DISPERSION COMPRISING AN ANTICANCER COMPOUND FOR IMPROVED SOLUBILITY AND EFFICACY
    Publication number: 20210308116
    Abstract: The present invention is related to the novel solid dispersion formulations of an anticancer compound of formula A and a process for preparing the same wherein the anticancer compound is formulated with hydrophilic polymer. The said formulation showed enhanced dissolution of the anticancer compound and improved in-vivo anticancer activity. The said formulations are useful for the treatment of various types of cancer.
    Type: Application
    Filed: June 14, 2019
    Publication date: October 7, 2021
    Inventors: Sonali Sandip BHARATE, Vikas KUMAR, Mubashir Javed MINTOO, Dilip Manikrao MONDHE, Sandip Bibishan BHARATE, Ram VISHWAKARMA
  • Fused pyrimidines as isoform selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof
    Patent number: 10696688
    Abstract: The present invention relates to fused pyrimidines of formulae I and II wherein, R1, R2 are as herein described. The present invention particularly relates to isoform selective PI3K? inhibition and their medicinal use as anticancer agents.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 30, 2020
    Assignee: Council of Scientific & Industrial Research
    Inventors: Sandip Bibishan Bharate, Shashi Bhushan, Shabber Mohammed, Santosh Kumar Guru, Sonali Sandip Bharate, Vikas Kumar, Girish Mahajan, Mubashir Javed Mintoo, Dilip Manikrao Mondhe, Ram Vishwakarma
  • FUSED PYRIMIDINES AS ISOFORM SELECTIVE PHOSPHOINOSITIDE-3-KINASE-ALPHA INHIBITORS AND PROCESS FOR PREPARATION THEREOF
    Publication number: 20200031845
    Abstract: The present invention relates to fused pyrimidines of formulae I and II wherein, R1, R2 are as herein described. The present invention particularly relates to isoform selective PI3K? inhibition and their medicinal use as anticancer agents.
    Type: Application
    Filed: November 21, 2016
    Publication date: January 30, 2020
    Inventors: Sandip Bibishan BHARATE, Shashi BHUSHAN, Shabber MOHAMMED, Santosh Kumar GURU, Sonali Sandip BHARATE, Vikas KUMAR, Girish MAHAJAN, Mubashir Javed MINTOO, Dilip Manikrao MONDHE, Ram VISHWAKARMA
  • 1,3,5 -triazine based PI3K inhibitors as anticancer agents and a process for the preparation thereof
    Patent number: 9951040
    Abstract: The present invention describes heterocyclic compounds of general Formula 1 and their method of preparation thereof. The present invention describes general Formula 1 which inhibits phosphoinositide 3-kinase (PI3K) and can be used as the anticancer agents.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: April 24, 2018
    Assignee: Council of Scientific and Industrial Research
    Inventors: Thanusha Thatikonda, Suresh Kumar, Umed Singh, Priya Mahajan, Girish Mahajan, Amit Nargotra, Fayaz Malik, Dilip Manikrao Mondhe, Ram Asrey Vishwakarma, Parvinder Pal Singh
  • NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF
    Publication number: 20170342049
    Abstract: The present invention describes heterocyclic compounds of general Formula 1 and their method of preparation thereof. The present invention describes general Formula 1 which inhibits phosphoinositide 3-kinase (PI3K) and can be used as the anticancer agents.
    Type: Application
    Filed: November 17, 2015
    Publication date: November 30, 2017
    Inventors: Thanusha Thatikonda, Suresh Kumar, Umed Singh, Priya Mahajan, Girish Mahajan, Amit Nargotra, Fayaz Malik, Dilip Manikrao Mondhe, Ram Asrey Vishwakarma, Parvinder Pal Singh
  • 2-anilino nicotinyl linked 2-amino benzothiazole conjugates and process for the preparation thereof
    Patent number: 9029553
    Abstract: The present invention provides compounds of general formula A useful as potential anticancer agents against human cancer cell lines and apoptosis inducers. The present invention further provides a process for the preparation of 2-anilino nicotinyl linked 2-amino benzothiazole conjugates of general formula (A), wherein R1?H or Cl; R2?H, OCH3 or F; R3?H, OCH3, F or Cl; R4?H, OCH3 or F and X?OCH3, F or N02.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: May 12, 2015
    Assignee: Council of Scientific & Industrial Research
    Inventors: Ahmed Kamal, Yellamelli Valli Venkata Srikanth, Mohammed Naseer Ahmed Khan, Mohammed Ashraf, Irum Sehar, Gousia Chashoo, Parduman Raj Sharma, Abid Hamid Dar, Bhushan Shashi, Shashank Kumar Singh, Dilip Manikrao Mondhe, Ajit Kumar Saxena
  • 2-ANILINO NICOTINYL LINKED 2-AMINO BENZOTHIAZOLE CONJUGATES AND PROCESS FOR THE PREPARATION THEREOF
    Publication number: 20130324734
    Abstract: The present invention provides compounds of general formula A useful as potential anticancer agents against human cancer cell lines and apoptosis inducers. The present invention further provides a process for the preparation of 2-anilino nicotinyl linked 2-amino benzothiazole conjugates of general formula (A), wherein R1?H or CI; R2?H, OCH3 or F; R3?H, OCH3, F or CI; R4?H, OCH3 or F and X?OCH3, F or N02.
    Type: Application
    Filed: March 30, 2011
    Publication date: December 5, 2013
    Inventors: Ahmed Kamal, Yellamelli Valli Venkata Srikanth, Mohammed Naseer Ahmed Khan, Mohammed Ashraf, Irum Sehar, Gousia Chashoo, Parduman Raj Sharma, Abid Hamid Dar, Bhushan Shashi, Shashank Kumar Singh, Dilip Manikrao Mondhe, Ajit Kumar Saxena
  • USE OF SEMI SYNTHETIC ANALOGUES OF BOSWELLIC ACIDS FOR ANTICANCER ACTIVITY
    Publication number: 20090298938
    Abstract: The present invention relates to use of compounds of general formula 1 for anticancerous activity, wherein the said compound being derived semi-synthetically from natural triterpenoic acids known as boswellic acids by the induction of apoptosis thereof cytotoxicity and anti-cancer activity displayed by semi-synthetic analogues of natural triterpenes, known as Boswellic acids. These compounds may be used for the treatment of cancer, alone or in combination with pharmaceutically acceptable or other carriers, displaying cytotoxicity and anti-cancer activity for colon, prostrate, liver, breast, central nervous system (CNS), leukemia and malignancy of other tissues, including ascites and solid tumors. The cancer cell death is mediated by induction of apoptosis and inhibition of cell proliferation at specific doses.
    Type: Application
    Filed: March 10, 2009
    Publication date: December 3, 2009
    Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Ghulam Nabi Qazi, Subhash Chandra Taneja, Jaswant Singh, Ajit Kumar Saxena, Vijay Kumar Sethi, Bhahwal Ali Shah, Bal Krishan Kapahi, Samar Singh Andotra, Ajay Kumar, Shashi Bhushan, Fayaz Malik, Dilip Manikrao Mondhe, Shanmugavel Muthiah, Surjeet Singh, Monika Verma, Shashank Kumar Singh
  • Hepatocurative effect of emblica officinalis against CYP 450 bio-activation hepatotoxicity of drugs
    Publication number: 20080138452
    Abstract: The present invention relates to a composition useful for hepatocurative effect against CYP 450 bio-activation hepatotoxicity induced by drugs, said composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives and method of treating drug induced hepatotoxicity
    Type: Application
    Filed: December 21, 2007
    Publication date: June 12, 2008
    Inventors: Rakesh Kamal Johri, Sheikh Tasaduq Abdullah, Kuldeep Singh, Devinder Kumar Gupta, Bal Krishan Kapahi, Dilip Manikrao Mondhe, Satinder Mohan Jain, Om Parkash Suri, Kasturi Lal Bedi, Ghulam Nabi Qazi
  • Hepatocurative effect of against CYP 450 bio-activation hepatotoxicity of drugs
    Patent number: 7001619
    Abstract: The present invention relates to a composition useful for hepatocurative effect against CYP 450 bio-activation hepatotoxicity induced by drugs, said composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives and method of treating drug induced hepatotoxicity.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: February 21, 2006
    Assignee: Council of Scientific and Industrial Research
    Inventors: Rakesh Kamal Johri, Sheikh Tasaduq Abdullah, Kuldeep Singh, Devinder Kumar Gupta, Bal Krishan Kapahi, Dilip Manikrao Mondhe, Satinder Mohan Jain, Om Parkash Suri, Kasturi Lal Bedi, Ghulam Nabi Qazi
  • Hepatocurative effect of emblica officinalis against CYP 450 bio-activation hepatotoxicity of drugs
    Publication number: 20030185922
    Abstract: The present invention relates to a composition useful for hepatocurative effect against CYP 450 bio-activation hepatotoxicity induced by drugs, said composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives and method of treating drug induced hepatotoxicity
    Type: Application
    Filed: March 27, 2002
    Publication date: October 2, 2003
    Inventors: Rakesh Kamal Johri, Sheikh Tasaduq Abdullah, Kuldeep Singh, Devinder Kumar Gupta, Bal Krishan Kapahi, Dilip Manikrao Mondhe, Satinder Mohan Jain, Om Parkash Suri, Kasturi Lal Bedi, Ghulam Nabi Qazi